
Cancer Education · Research
Rethinking Glioblastoma Care: Methylation Status, Tumor Treating Fields, and IDH Inhibitors
Glioblastoma outcomes with temozolomide depend heavily on MGMT methylation status, a distinction worth revisiting given how often it gets lost in practice.
By Jerome Graber, MD, MPH





























